Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 10:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 7,007 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Urologic Diseases Clear all
Not yet recruiting Not applicable Interventional

Trial of NASHA Dx Urethral Bulking System

NCT07850804
View directory record Official record
Conditions
Urinary Incontinence, Urinary Incontinence (UI), Urinary Incontinence , Stress, Urinary Incontinence Due to Urethral Sphincter Incompetence, Urethral Sphincter Activity, Intrinsic Sphincter Deficiency, Pelvic Floor Dysfunction
Interventions
NASHA Dx, Bulkamid
Device
Lead sponsor
Palette Life Sciences, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
Tustin, California • Lincoln, Nebraska • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 15, 2026, 10:04 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Zemplar Capsule in Reducing Serum IPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)

NCT00048438
View directory record Official record
Conditions
Renal Insufficiency, Chronic
Interventions
paricalcitol
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
17
States / cities
Orange, California • Thornton, Colorado • Hudson, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2006 · Synced Oct 15, 2026, 10:04 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

NCT03022825
View directory record Official record
Conditions
Bladder Cancer
Interventions
N-803 and BCG, N-803
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
28
States / cities
Anchorage, Alaska • Little Rock, Arkansas • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 15, 2026, 10:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study of AR882 in Subjects With Various Degrees of Renal Impairment

NCT04646889
View directory record Official record
Conditions
Renal Impairment
Interventions
AR882 Single Dose, AR882 Multiple Dose
Drug
Lead sponsor
Arthrosi Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Orlando, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2022 · Synced Oct 15, 2026, 10:04 AM EDT
Completed Phase 2 Interventional

A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder

NCT00321477
View directory record Official record
Conditions
Incontinence, Urinary and Urinary Bladder, Overactive, Overactive Bladder
Interventions
GW679769 oral tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
41
States / cities
Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2017 · Synced Oct 15, 2026, 10:04 AM EDT
Completed Early Phase 1 Interventional

Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer

NCT03473730
View directory record Official record
Conditions
Bladder Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma, Malignant Urinary System Neoplasm, Metastatic Kidney Carcinoma, Stage IV Renal Cell Cancer AJCC V8
Interventions
Biopsy, Daratumumab, Laboratory Biomarker Analysis, Metastasectomy, Nephrectomy
Procedure · Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Oct 15, 2026, 10:04 AM EDT
Recruiting No phase listed Observational

Patient-Derived Xenografts to Reduce Cancer Health Disparities

NCT04410302
View directory record Official record
Conditions
Bladder Carcinoma, Gastric Carcinoma, Liver and Intrahepatic Bile Duct Carcinoma, Lung Carcinoma, Malignant Neoplasm
Interventions
Biospecimen Collection
Procedure
Lead sponsor
University of California, Davis
Other
Eligibility
21 Years to 100 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Orange, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 15, 2026, 10:04 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer

NCT01780545
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma
Interventions
OGX-427, Docetaxel
Drug
Lead sponsor
Noah Hahn, M.D.
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
35
States / cities
Birmingham, Alabama • Duarte, California • Lancaster, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Oct 15, 2026, 10:04 AM EDT
Completed No phase listed Observational

Health-related Quality of Life in Rare Kidney Stone

NCT02124395
View directory record Official record
Conditions
Primary Hyperoxaluria, Cystinuria, Adenine Phosphoribosyl Transferase Deficiency, Dent Disease
Interventions
Health-related Quality of Life in Rare Kidney Stone Questionnaire
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
5 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
2
States / cities
Rochester, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 2, 2022 · Synced Oct 15, 2026, 10:04 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus Nephritis

NCT00573157
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Atacicept, Mycophenolate mofetil, Placebo, Corticosteroids
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
16 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
12
States / cities
New Orleans, Louisiana • Shreveport, Louisiana • Detroit, Michigan + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2016 · Synced Oct 15, 2026, 10:04 AM EDT
Completed No phase listed Observational

Observational Study of Kibow Biotics in Chronic Kidney Failure Patients

NCT01450657
View directory record Official record
Conditions
Chronic Kidney Failure
Interventions
Kibow Biotics/Renadyl
Dietary Supplement
Lead sponsor
Kibow Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 18, 2017 · Synced Oct 15, 2026, 10:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants.

NCT07032272
View directory record Official record
Conditions
Autoimmune and Chronic Inflammatory Diseases
Interventions
remibrutinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
4
States / cities
Miami, Florida • Miami Lakes, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 15, 2026, 10:04 AM EDT
Completed No phase listed Observational Results available

Longer-term Recurrence Rates in Patients With Bladder Cancer After Hexvix (Cysview)Fluorescence Cystoscopy/TURB

NCT01166230
View directory record Official record
Conditions
Bladder Cancer
Interventions
Not listed
Lead sponsor
Photocure
Industry
Eligibility
18 Years and older
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
14
States / cities
Stanford, California • Gainesville, Florida • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Oct 15, 2026, 10:04 AM EDT
Completed Not applicable Interventional

Pilot to Examine Risk and Feasibility of Remote Management of BP From Childhood Into Early Adulthood

NCT03691701
View directory record Official record
Conditions
Chronic Kidney Diseases, Hypertension, Blood Pressure
Interventions
strict blood pressure control
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
13 Years to 30 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 15, 2026, 10:04 AM EDT
Completed Phase 2 Interventional

A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy

NCT02552277
View directory record Official record
Conditions
Diabetic Nephropathies, Peripheral Nervous System Diseases
Interventions
PDA-002, Placebo
Biological · Drug
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
7
States / cities
Garden Grove, California • Orange, California • Orlando, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2022 · Synced Oct 15, 2026, 10:04 AM EDT
Terminated Phase 4 Interventional Results available

A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment

NCT03226899
View directory record Official record
Conditions
Gout, Chronic Kidney Disease (CKD)
Interventions
Lesinurad, XOI, Placebo, colchicine, corticosteroids
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
70
States / cities
Birmingham, Alabama • Tucson, Arizona • Covina, California + 59 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 15, 2026, 10:04 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)

NCT02592798
View directory record Official record
Conditions
Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, Minimal Change Disease
Interventions
Abatacept, Normal Saline, D5W
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
6 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
27
States / cities
Birmingham, Alabama • Torrance, California • Aurora, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 15, 2026, 10:04 AM EDT
Completed Not applicable Interventional

Superficial Peroneal Nerve Neuromodulation for Non-Obstructive Urinary Retention

NCT04000763
View directory record Official record
Conditions
Urinary Retention, Urinary Bladder, Underactive
Interventions
superficial peroneal nerve stimulation
Device
Lead sponsor
Christopher J Chermansky, MD
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Oct 15, 2026, 10:04 AM EDT
Completed Phase 2 Interventional Results available

Factor XI LICA to Reduce Events Such as Heart Attack and Stroke in Patients Whose Kidneys Are no Longer Able to Work as They Should and Require Treatment to Filter Wastes From the Blood: Focus is on the Safety of BAY2976217 and the Way the Body Absorbs, Distributes and Removes the Study Drug

NCT04534114
View directory record Official record
Conditions
End Stage Renal Disease Requiring Hemodialysis
Interventions
Fesomersen sodium (BAY2976217), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
9
States / cities
Clovis, California • Victorville, California • Fort Lauderdale, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 15, 2026, 10:04 AM EDT
Completed Phase 2 Interventional Results available

Effectiveness of the Investigational Drug Campath-1H in Preventing Rejection of Transplanted Kidneys

NCT00001984
View directory record Official record
Conditions
Graft Rejection, Kidney Disease
Interventions
Alemtuzumab and DSG
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Oct 15, 2026, 10:04 AM EDT
Completed Not applicable Interventional Results available

Return of Continence Following Robot-Assisted Radical Prostatectomy With or Without a Urethrovesical Sling

NCT00937833
View directory record Official record
Conditions
Urinary Incontinence, Prostate Cancer
Interventions
Prostatectomy, Surgisis Male Sling
Procedure · Device
Lead sponsor
Cook Group Incorporated
Industry
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Indianapolis, Indiana • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 29, 2014 · Synced Oct 15, 2026, 10:04 AM EDT
Terminated Phase 2 Interventional

Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Bladder

NCT00003452
View directory record Official record
Conditions
Stage IV Bladder Cancer
Interventions
Antineoplaston therapy (Atengenal + Astugenal)
Drug
Lead sponsor
Burzynski Research Institute
Other
Eligibility
18 Years to 99 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1998
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2017 · Synced Oct 15, 2026, 10:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Analysis of Calcium Balance in Chronic Kidney Disease

NCT00974532
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
High calcium diet 2000 mg/day, Low calcium diet, 800 mg/day
Dietary Supplement
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 5, 2012 · Synced Oct 15, 2026, 10:04 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of GSK1278863 in Recombinant Human Erythropoietin (rhEPO) Hyporesponsive Hemodialysis-dependent Chronic Kidney Disease Subjects With Anemia

NCT02075463
View directory record Official record
Conditions
Anemia, Anaemia
Interventions
GSK1278863, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Azusa, California • Glendale, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 15, 2026, 10:04 AM EDT